Cancer stem cells as a research center in immunotherapy

The evidence supports the hypothesis of the cancer stem cells, which postulate that they are responsible for the initiation, the recurrence, metastasis and the resistance to anti neoplasia treatments, creating the need for therapies aimed specifically at these subpopulations of cells with characteristics of stem cells within the most heterogeneous malignant tumors. Within tumors subsets of the cells transformed in neoplasia show the expression on its surface of molecules that are not typically present on the surface of the surrounding normal cells. In some cases, especially in the malignant melanomas, the lymphocytes T cytotoxic directed against these antigens associated with tumors have been isolated to create antibodies and somehow reduce the disease. The approach to vaccine against cancer therapy is based on the idea that the immune system could saddle a rejection response force against the conglomerate of the cells transformed neoplasia. The new markers that are safe and allow direct immunotherapy for eradication of the tumor, with the combination of many therapies, and thus have an efficient outcome in the treatment of this disease is currently looking for.